Name (Synonyms) | Correlation | |
---|---|---|
drug2558 | Trauma-informed yoga video recording Wiki | 1.00 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
There is a lack of knowledge about how many children are infected with SARS-CoV-2, how often they are asymptomatic, and how long the immunity persists. The main purpose of this study is to measure antibodies to SARS-CoV-2, symptoms, and risk factors in a representative cohort of children and adolescents in the canton of Zurich, Switzerland, shortly after re-opening of the school system and thereafter. The study also investigates antibodies to SARS-CoV-2 in parents of the children and school personnel.
Description: Seroprevalence of SARS-CoV-2 IgG, IgM and/or IgA antibodies in randomly selected 5- to 16-year-old population of school-children, their parents, and school personnel, after the peak phase of the first major wave shortly after re-opening of schools in the canton of Zürich, Switzerland.
Measure: Seroprevalence of SARS-CoV-2 IgG, IgM and/or IgA antibodies Time: at inclusionDescription: Seroprevalence of SARS-CoV-2 IgG, IgM and/or IgA antibodies in randomly selected 5- to 16-year-old population of school-children and school personnel after 4-5 after recruitement in the canton of Zürich, Switzerland.
Measure: Seroprevalence of SARS-CoV-2 IgG, IgM and/or IgA antibodies Time: Month 4-5Description: Seroprevalence of SARS-CoV-2 IgG, IgM and/or IgA antibodies in randomly selected 5- to 16-year-old population of school-children and school personnel after 8-9 months after recruitment in the canton of Zürich, Switzerland.
Measure: Seroprevalence of SARS-CoV-2 IgG, IgM and/or IgA antibodies Time: Month 8-9Description: Presence of symptoms (from January 2020) suggestive of a common cold, influenza and similar upper respiratory tract infections prior to the first study visit.
Measure: Presence of self-reported symptoms Time: at inclusionDescription: Proportion of seropositive children reporting symptoms suggestive of a common cold, influenza and similar upper respiratory tract infections between January 2020 and first study visit.
Measure: Proportion of seropositive children reporting COVID-19 related symptoms from January 2020 Time: at inclusionDescription: Presence of symptoms (from January 2020) suggestive of a common cold, influenza and similar upper respiratory tract infections during the follow-up.
Measure: Presence of self-reported symptoms Time: within 9 months of follow-upDescription: Incidence of self-reported symptoms and SARS-CoV-2 infections after the first study visit in initially seropositive participants.
Measure: Incidence of symptoms in initially seropositive participants Time: within 9 months of follow-upDescription: Proportion of seronegative participants of the first investigation wave who will self-report symptoms and infection with SARS-CoV-2.
Measure: Proportion of participants, seronegative at inclusion, with symptoms in the follow-up Time: within 9 months of follow-upDescription: Potential personal (socioeconomic characteristics, health status, presence of infection in family, personal hygiene and social distancing measures) and school-level (implementation of informational, social distancing and hygiene measures at school) risk and preventive factors for SARS-CoV-2 infection prior to the study. Questionnaire includes HBSC and custom questions.
Measure: Presence of risk factors for infection at inclusion (assessment via custom questionnaire) Time: at inclusionDescription: Potential personal (socioeconomic characteristics, health status, presence of infection in family, personal hygiene and social distancing measures) and school-level (implementation of informational, social distancing and hygiene measures at school) risk and preventive factors for SARS-CoV-2 infection during the follow-up. Questionnaire includes HBSC and custom questions.
Measure: Presence of risk factors for infection during follow-up (assessment via custom questionnaire) Time: within 9 months of follow-upDescription: Changes in lifestyle during the lock-down, compared to prior to it: frequency and duration (in hours, daily) of physical activity, duration (in hours, daily) of sleep, duration of screen-based media-use (in hours, daily). This outcome is measured only in the children population.
Measure: Self-reported lifestyle changes of participants at inclusion Time: at inclusionDescription: Changes in lifestyle after the lock-down and school reopening, compared to during lock-down: frequency and duration (in hours, daily) of physical activity, duration (in hours, daily) of sleep, duration of screen-based media-use (in hours, daily). This outcome is measured only in the children population.
Measure: Self-reported lifestyle changes of participants during follow-up Time: within 9 months of follow-upDescription: Changes over the study time in mental well-being of the participants during and after the lock-down: frequency scale (never/rarely/sometimes/often/always) of self-reported stress, anxiety, self-confidence feelings in the last 7 days. This outcome is measured only in the children population.
Measure: Self-reported mental well-being (KINDL questionnaire) Time: within 9 months of follow-upDescription: Changes over the study time in mental well-being of the participants during and after the lock-down: frequency scale (daily/weekly/monthly/rarer) of self-reported sadness, anxiety and sleeping problems (HBSC questionnaire question on mental well-being). This outcome is measured only in the children population.
Measure: Self-reported mental well-being (HBSC questionnaire) Time: within 9 months of follow-upDescription: Changes over the study time in quality-of-life of the participants during and after the lock-down: frequency scale (never/rarely/sometimes/often/always) assessment of self-reported positive and negative social interactions with family, friends and in the school environment in the last 7 days. This outcome is measured only in the children population.
Measure: Self-reported quality of life (KINDL questionnaire) Time: within 9 months of follow-upDescription: Prevalence of clusters of seropositive children, adolescents, and school personnel within schools and classes at baseline.
Measure: Prevalence of seropositive SARS-Cov-2 clusters in schools at inclusion Time: at inclusionDescription: Incidence of clusters of seropositive children, adolescents, and school personnel within schools and classes during the follow-up.
Measure: Incidence of seropositive SARS-Cov-2 clusters in schools during the follow-up Time: within 9 months of follow-upDescription: Impact of the number of children/adolescents and school personnel at a specific period (baseline, at the second and third testing date) within a school or class to the subsequent seropositivity within the same group.
Measure: Change in seropositive participants within school or class, depending on the initial proportion of seropositive participants Time: within 9 months of follow-upDescription: Incidence of seropositive children and school personnel according to potential risk factors and preventive measures for SARS-CoV-2 infection within schools.
Measure: Effect of risk factors and preventive measures on SARS-CoV-2 infection incidence within schools Time: within 9 months of follow-up